Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite owns generic which have been licensed to TAGI Pharma and Glenmark Pharmaceuticals Inc., USA., and Lannett Company, Inc.
Elite currently has twelve approved generic products, four generic products filed with the FDA, one approved generic product pending manufacturing site transfer, and the NDA filing for SequestOx™.
Elite’s pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse.
Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.